Skip to main content

Table 1 Characteristics of patients enrolled in study

From: Evaluation of 18F-fluorothymidine positron emission tomography ([18F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer

Pt No Age (years) Sitea Stageb Chemotherapyc Overall RECIST responsed SUV60, ave (preRx) SUV60, max (preRx) Percentage Change SUV60, ave Percentage Change SUV60, max Baseline FDG SUV60, ave Baseline FDG SUV60,max Ki-67 (%)
1 63 GEJ T4N1M1 EOX PR 5.92 9.45 −35.16 −54.49 43
2 54 Distal T3N0 ECX, surgery 4.6 4.52 −25.65 −5.75 5.93 4.38
3 68 Distal T3N0M1 EOX SD 5.32 7.47 −2.26 4.95 6.76 5.63 87
4 76 GEJ T3N1M1 ECX PR 4.97 7.25 6.44 5.66 21.45 19.96 29
5 71 GEJ T3N0M0 EOX SD 6.08 9.96 11.51 11.14 14.91 14.06 23
6 64 GEJ T4N1M1 EOX SD 5.5 8.85 −30.73 −47.57 10.44 9.03
7 65 Gastric T3N1M0 EOX, Surgery PR 4.14 7.62 −15.22 −16.93
7e       3.65 8.87 1.92 29.76    
8 60 Distal T3N1M0 ECX, surgery SD 7.7 13.36 −29.61 −33.08
9 54 Gastric T3N1M0 EOX/STO3 SD 3.66 5.93 −24.86 −25.46 51
10 69 Distal T3N0M0 ECX, surgery SD 4.79 9.3 −18.99 −24.09 13.88 12.24 67.5
  1. a GEJ gastro-oesophageal junction, distal distal oesophagus
  2. bStage according to TNM criteria, CT and EUS used
  3. c EOX epirubicin, oxaliplatin and capecitabine, ECX epirubicin, cisplatin and capecitabine, ST03 study - ECX +/- bevacizumab
  4. dRECIST criteria: PR partial response, SD stable disease, PD progressive disease
  5. eLymph node >20 mm, included as a target lesion in final analysis